Published in PLoS One on May 23, 2014
Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer (2015) 0.87
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood (2016) 0.87
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol (2016) 0.85
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol (2016) 0.83
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target. Am J Cancer Res (2015) 0.82
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. J Med Chem (2015) 0.80
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Histone modifications as regulators of life and death in Saccharomyces cerevisiae. Microb Cell (2015) 0.75
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget (2016) 0.75
Targeting human SET1/MLL family of proteins. Protein Sci (2017) 0.75
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. Mol Clin Oncol (2017) 0.75
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol (2000) 13.46
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem (2001) 8.78
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev (2004) 7.57
Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem (2001) 7.35
Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature (2004) 6.72
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene (2001) 4.70
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol (2008) 4.56
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry (2000) 2.84
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev (2008) 2.41
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
Histone H3 lysine 4 (H3K4) methylation in development and differentiation. Dev Biol (2009) 2.24
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet (2004) 2.05
BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ (2006) 1.97
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res (2003) 1.86
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer (2010) 1.77
Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. J Cell Physiol (2005) 1.66
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
Evolving ideas about cyclins. Cell (1999) 1.45
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36
Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem (2012) 1.26
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer (2008) 1.24
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia (2011) 1.21
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol (2010) 1.13
Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J (2012) 1.10
Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis. Cancer Res (1998) 1.10
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest (2009) 1.07
FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood (2012) 0.97
Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res (2012) 0.95
Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L. Medchemcomm (2013) 0.95
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol Pharmacol (2007) 0.91
The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia. Haematologica (2013) 0.86